

June 12, 2026

National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400051

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai- 400001

Symbol: LALPATHLAB

Scrip Code: 539524

**Subject: Update on Incorporation of Wholly Owned Subsidiary Company**  
**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)**  
**Regulations, 2015 (“the Listing Regulations”)**

Dear Sir/ Madam,

This is in continuation to our earlier intimation dated April 30, 2026, wherein we have informed that the Board of Directors of the Company has approved for incorporating a Wholly Owned Subsidiary (“WOS”) Company in Dubai, United Arab Emirates.

We wish to inform you that the WOS has been incorporated in the name of “DR LAL PATHLABS FZCO” on June 12, 2026 and the Company has received the Certificate of Incorporation/Licence on the even date from the relevant Dubai Multi Commodities Centre (“DMCC”), authority.

The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as amended from time to time is enclosed herewith as “**Annexure – A**”

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

**Vinay Gujral**  
**Company Secretary & Compliance Officer**  
Encl.: As above

**DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:**

<b>SN</b>	<b>Particulars</b>	<b>Acquisition of Company</b>
1	Name of the target entity, details in brief such as size, turnover etc.	<b>Name of the incorporated entity:</b> DR LAL PATHLABS FZCO  <b>Turnover, size:</b> Not applicable since it is a newly incorporated company.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Not Applicable since this Intimation is regarding the Incorporation of the wholly owned subsidiary of the Company.
3	Industry to which the entity being acquired belongs	Diagnostic Services
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Wholly Owned Subsidiary intends to strategically invest in Diagnostics and allied activities. This includes exploring potential acquisitions, tie-ups, or joint ventures.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration
8	Cost of acquisition and/or the price at which the shares are acquired	The Company has subscribed to the share capital of DR LAL PATHLABS FZCO amounting to AED 1,91,35,000 divided into 19,135 shares of AED 1,000 each.
9	Percentage of shareholding / control acquired and / or number of shares acquired	100% shareholding is held by Dr. Lal PathLabs Limited



10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>DR LAL PATHLABS FZCO is Wholly Owned Subsidiary intends to strategically invest in Diagnostics and allied activities. This includes exploring potential acquisitions, tie-ups, or joint ventures.</p> <p>Date of Incorporation: June 12, 2026</p> <p>Turnover: Not applicable (newly incorporated company).</p> <p>Country: Dubai, United Arab Emirates</p>
----	--	--